SubsidieMeestersIn Silico Trials for Cartilage Regenerative Medicine Applications
The INSTAnt CARMA project aims to develop and validate a multiscale in silico model for osteoarthritis to optimize drug and tissue-engineered therapies through virtual trials.
Projectdetails
Introduction
Osteoarthritis (OA) is a highly prevalent disease, affecting 1 in 8 adults worldwide and is projected to increase by 60% in the next two decades. Due to the intricate interplay between multiple influencing factors such as mechanical loading and inflammation playing out over multiple length scales and tissue compartments, currently no disease-modifying drugs are available on the market.
Project Overview
The INSTAnt CARMA project aims to harness the power of in silico trials to study OA onset and progression, as well as design endogenous (drugs) and exogenous (tissue engineered) therapies.
Model Development
A multiscale multifactorial in silico model of the knee joint will be established and validated with dedicated in vitro and in vivo experiments. A continuous effort following targeted and untargeted approaches will take place to explore biological hypotheses and implement relevant model extensions.
Computational Tools
In parallel, computational upscaling tools will be implemented to prepare the model for execution of in silico trial simulations on virtual patient cohorts.
In Silico Trials
- The first in silico trial will investigate the effect of model-predicted drug combinations after experimental confirmation in a rodent model.
- The second trial will seek to optimize tissue engineered constructs for deep osteochondral defect regeneration, followed by experimental validation in a small and large animal model.
Resources and Impact
To realize its goals, INSTAnt CARMA can build on the well-received and published work on a wide range of in silico, in vitro and in vivo tools developed by the applicant and her team.
Networking and Regulatory Science
Additionally, the work will benefit from the applicant’s extensive network and involvement in regulatory science for in silico medicine. This project will further accelerate the uptake of in silico testing strategies in the development of medical therapies in general and osteoarthritis in particular.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.212.385 |
| Totale projectbegroting | € 2.212.385 |
Tijdlijn
| Startdatum | 1-9-2023 |
| Einddatum | 31-8-2028 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITE DE LIEGEpenvoerder
- KATHOLIEKE UNIVERSITEIT LEUVEN
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Restoring the structural collagen network in the regeneration of cartilageRe-COLL aims to develop durable implants for damaged joints by engineering anisotropic collagen networks through biofabrication and in vitro models, enhancing tissue regeneration and stability. | ERC Advanced... | € 2.500.000 | 2024 | Details |
Using CARDIac simulations to run in-silicO clinical TRIALSThis project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials. | ERC Starting... | € 1.499.423 | 2022 | Details |
Regulation of Articular Cartilage Zonal Emergence: Harnessing Developmental Pathways to Enhance RegenerationReZone aims to uncover the mechanisms of zonal emergence in articular cartilage using a goat model to enhance regeneration and improve treatment for cartilage injuries. | ERC Consolid... | € 2.265.746 | 2024 | Details |
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovationMETA-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time. | ERC Starting... | € 1.499.884 | 2024 | Details |
Disruptive Therapies for the long-term relief of Osteoarthritis PainThe Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life. | ERC Consolid... | € 1.998.885 | 2023 | Details |
Restoring the structural collagen network in the regeneration of cartilage
Re-COLL aims to develop durable implants for damaged joints by engineering anisotropic collagen networks through biofabrication and in vitro models, enhancing tissue regeneration and stability.
Using CARDIac simulations to run in-silicO clinical TRIALS
This project aims to develop a GPU-accelerated computational platform for simulating cardiac pathologies and device responses, integrating uncertainty quantification to enhance in-silico clinical trials.
Regulation of Articular Cartilage Zonal Emergence: Harnessing Developmental Pathways to Enhance Regeneration
ReZone aims to uncover the mechanisms of zonal emergence in articular cartilage using a goat model to enhance regeneration and improve treatment for cartilage injuries.
Development of a lung METAstasis-on-a-CHIP model for osteosarcoma as a biomimetic testing platform for drug discovery and therapeutic innovation
META-CHIP aims to develop a lung metastasis-on-a-chip model for osteosarcoma to enhance drug development and predict patient responses to therapies in real-time.
Disruptive Therapies for the long-term relief of Osteoarthritis Pain
The Arth-Alleve project aims to develop a non-pharmaceutical, long-term therapy using neurotoxin-loaded hydrogels to effectively manage chronic pain in osteoarthritis patients, improving their quality of life.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
INTELLECTUALSDit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis. | 1.1 - Het ve... | € 479.529 | 2024 | Details |
Development of a Complete Triple Action Injectable Treatment for OsteoarthritisRelevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients. | EIC Transition | € 2.398.115 | 2022 | Details |
NCM for osteoarthritisNC Biomatrix onderzoekt een innovatieve therapie voor artrose met notochordale cellen om pijn aan te pakken en kraakbeen te herstellen. | Mkb-innovati... | € 20.000 | 2021 | Details |
Bestrijding Artrose met Operatie RobotsDit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
A breakthrough active immunotherapy for the treatment of osteoarthritisPeptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
INTELLECTUALS
Dit project ontwikkelt een innovatief kraakbeen-op-een-chip model voor gepersonaliseerde behandelingen van osteoartritis.
Development of a Complete Triple Action Injectable Treatment for Osteoarthritis
Relevium Ltd aims to validate and commercialize Hydrobloc, a unique therapy that regenerates cartilage, alleviates pain, and improves joint function in osteoarthritis patients.
NCM for osteoarthritis
NC Biomatrix onderzoekt een innovatieve therapie voor artrose met notochordale cellen om pijn aan te pakken en kraakbeen te herstellen.
Bestrijding Artrose met Operatie Robots
Dit project onderzoekt de haalbaarheid van het aanpassen van operatie robots voor de behandeling van artrose, met als doel precisie, kostenbesparing en gezondheidsvoordelen te realiseren.
A breakthrough active immunotherapy for the treatment of osteoarthritis
Peptinov aims to halt osteoarthritis progression through a cost-effective immunotherapy that neutralizes IL-6, with promising Phase I results leading to a Phase II trial for out-licensing readiness.